Skip to main content

Table 3 Survival-related characteristics in advanced HG-SOCs who underwent NAC/IDS

From: Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Variable

Univariate

Multivariate

PFS

OS

PFS

OS

FIGO stage

 IV

1.00

(reference)

1.00

(reference)

1.00

(reference)

1.00

(reference)

 IIIc

3.03

(0.35–13.66)

4.24

(0.52–6.95)

2.28

(0.30–4.10)

3.57

(0.48–6.46)

Ascites

  > =500 ml

1.00

(reference)

1.00

(reference)

1.00

(reference)

1.00

(reference)

  < 500 ml

1.82

(1.45–2.85)

1.90

(1.56–2.98)

2.05

(1.40–2.95)

2.02

(1.66–4.08)

Outcome of surgery

 Suboptimal

1.00

(reference)

1.00

(reference)

1.00

(reference)

1.00

(reference)

 Optimal

1.52

(1.15–2.42)

1.66

(1.22–2.50)

1.93

(1.75–2.84)

2.20

(1.40–4.24)

Tumor sites

  > 3

1.00

(reference)

1.00

(reference)

1.00

(reference)

1.00

(reference)

  < = 3

1.32

(1.12–1.80)

1.49

(1.25–2.25)

1.26

(0.94–1.74)

1.40

(0.85–2.04)

Baseline CA-125

1.02

(1.01–1.08)

1.03

(1.01–1.08)

1.02

(0.97–1.07)

1.02

(0.98–1.06)

Preoperative CA-125

1.01

(1.00–1.04)

1.01

(1.00–1.04)

1.02

(0.96–1.05)

1.02

(0.96–1.05)

CA-125 decreasing kinetics

1.02

(1.00–1.04)

1.02

(1.00–1.04)

1.01

(1.00–1.04)

1.01

(1.00–1.05)